Your browser doesn't support javascript.
loading
Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study.
Scarduelli, Cleante; Inglese, Francesco; Beccaria, Massimiliano; Spreafico, Fabio; Garuti, Martina; Pecoriello, Antonietta; Cervi, Giulia; Greco, Graziana; Scarduelli, Sara; Lucchini, Giuseppe; De Donno, Giuseppe; Borghi, Claudio.
Afiliación
  • Scarduelli C; ASST Mantova. cleante@libero.it.
  • Inglese F; ASST Mantova Italy. francesco.inglese@asst-mantova.it.
  • Beccaria M; Pulmonology and Respiratory Intensive Care Unit ASST Mantova . massimiliano.beccaria@asst-mantova.it.
  • Spreafico F; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. fabio.spreafico@asst-mantova.it.
  • Garuti M; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. martina.garuti@asst-mantova.it.
  • Pecoriello A; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. antonietta.pecoriello@asst-mantova.it.
  • Cervi G; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. giulia.cervi@asst-mantova.it.
  • Greco G; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. graziana.greco@asst-mantova.it.
  • Scarduelli S; Internal Medicine Department of Medical and Surgical Sciences Bologna University . saran.y@hotmail.it.
  • Lucchini G; Bio-statistical Service, ASST, Mantova. giuseppe.lucchini@asst-mantova.it.
  • De Donno G; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. giuseppe.dedonno@asst-mantova.it.
  • Borghi C; Internal Medicine Department of Medical and Surgical Sciences Bologna University. claudio.borghi@unibo.it.
Monaldi Arch Chest Dis ; 91(3)2021 Mar 16.
Article en En | MEDLINE | ID: mdl-33728885
Coronavirus disease (COVID-19) may predispose patients to pulmonary embolism (PE), despite standard thromboprophylaxis. Our retrospective study aimed to report the prevalence of PE in patients with COVID-19 and severe respiratory failure (SRF) treated with intermediate- to full-dose enoxaparin. We analyzed data from patients with COVID-19 pneumonia and SRF admitted to our Respiratory Intensive Care Unit (RICU) from February 27 to April 20, 2020. All patients received at least intermediate-dose enoxaparin (40 mg twice daily). Computed tomography pulmonary angiography (CTPA) was used to detect PE. Ninety-two patients with COVID-19 pneumonia and SRF were admitted to our RICU. Twenty-two patients underwent CTPA (24 %), 11 of whom had PEs (12%). We hypothesize that the enoxaparin treatment may be responsible for the lower prevalence of PE as compared to previous reports of similar patients, even if our report had several limitations, mainly the small sample size.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Embolia Pulmonar / Tromboembolia Venosa / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Monaldi Arch Chest Dis Año: 2021 Tipo del documento: Article Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Embolia Pulmonar / Tromboembolia Venosa / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Monaldi Arch Chest Dis Año: 2021 Tipo del documento: Article Pais de publicación: Italia